| Literature DB >> 33012702 |
Hamin Jeong1, BoYoon Choi1, Jiyeon Lee1, Kyung Soo Kim2, Sung Jin Min2, Jin Kook Kim3.
Abstract
INTRODUCTION: Stamm's S-point is gaining importance as a bleeding focus in severe epistaxis. However, prevalence and features of S-point bleeding compared to non S-point bleeding have not been studied.Entities:
Keywords: Anemia; Body mass index; Emergency; Epistaxis; Nasal septum
Mesh:
Year: 2020 PMID: 33012702 PMCID: PMC9422729 DOI: 10.1016/j.bjorl.2020.07.008
Source DB: PubMed Journal: Braz J Otorhinolaryngol ISSN: 1808-8686
Figure 1(1) Endoscopic view of left nasal cavity. Bleeding at Superior portion of nasal septum, above the axilla of middle turbinate (S-point). (2) S-point cauterization was performed.
Figure 2Age distribution of S-point bleeding group and non S-point bleeding group.
Demographic distribution for S-point group and Non S-point group.
| 55.90 (±13.8) | 51.54 (±16.0) | 52.79 (±15.4) | |
| Male | 29 | 64 | 93 |
| Female | 11 | 35 | 46 |
Characteristics and treatments of S-point bleeding and Non S-point bleeding.
| HTN | 13 (32.5%) | 38 (38.4%) | 0.515 |
| DM | 5 (12.5%) | 6 (6.1%) | 0.203 |
| Anticoagulants | 4 (10.0%) | 10 (10.1%) | 1 |
| Direction | 0.699 | ||
| Left | 22 (55.0%) | 58 (58.6%) | |
| Right | 18 (45.0%) | 41 (41.4%) | |
| Sinonasal disease | 20 (50.0%) | 40 (40.4%) | 0.301 |
| Dyslipidemia | 3 (7.5%) | 11 (11.1%) | 0.757 |
| Thrombocytopenia | 1 (2.5%) | 3 (3.0%) | 1 |
| Initial treatment | 0.550 | ||
| Nasal packing | 20 (50.0%) | 57 (57.6%) | |
| Cauterization (L/A) | 10 (25.0%) | 25 (25.3%) | |
| Observation | 10 (25.0%) | 17 (17.2%) | |
| Final treatment | 0.763 | ||
| Nasal packing | 3 (7.5%) | 12 (12.1%) | |
| Cauterization (L/A) | 10 (25.0%) | 17 (17.2%) | |
| Observation | 7 (17.5%) | 18 (18.2%) | |
| Cauterization (G/A) | 17 (42.5%) | 40 (40.4%) | |
| Embolization | 3 (7.5%) | 12 (12.1%) |
L/A, Local Anesthesia; G/A, General Anestesia.
Univariable logistic regression analysis of S-point bleeding.
| 3.635 (1.669–7.9140) | 0.001 | |
| 8.559 (1.648–44.445) | 0.011 | |
| 0.773 (0.356–1.679) | 0.515 | |
| 2.214 (0.635–7.720) | 0.212 | |
| 0.989 (0.291–3.358) | 0.986 | |
| 1.157 (0.552–2.426) | 0.699 | |
| 1.475 (0.705–3.087) | 0.302 | |
| 0.649 (0.171–2.460) | 0.525 | |
| 0.821 (0.083–8.131) | 0.866 |
OR, Odds Ratio; 95% CI, Confidence Interval.
Underweight, BMI < 18.5.
Indicate statistically significant (p-value < 0.05).
BMI score and anemia grade of S-point group and Non S-point group.
| 0.010 | |||
| Underweight (BMI < 18.5) | 6 (15.0%) | 2 (2.0%) | |
| Normal (BMI 18.5 to 23) | 8 (20.0%) | 28 (28.3%) | |
| Overweight (BMI 23 to 25) | 12 (30.0%) | 19 (19.2%) | |
| Obesity (BMI >25) | 14 (35.0%) | 50 (50.5%) | |
| 0.001 | |||
| Normal Hb | 13 (32.5%) | 63 (63.6%) | |
| Anemia | 27 (67.5%) | 36 (36.4%) | |
| <0.001 | |||
| Normal Hb | 13 (32.5%) | 63 (63.6%) | |
| Mild anemia | 24 (60.0%) | 24 (24.2%) | |
| Moderate anemia | 3 (7.5%) | 7 (7.1%) | |
| Severe anemia | 0 (0%) | 5 (5.1%) |
BMI, Body Mass Index; Hb, Hemoglobin.
Normal Hb, Hb 12.0–16.0 g/dL for female and 14.0–18.0 g/dL for male; Mild anemia, Hb 10 g/dL to levels within normal limits; Moderate anemia, Hb 8–10 g/dL; Severe anemia, Hb 6.5–7.9 g/dL.
Indicate statistically significant (p-value < 0.05).
Mean initial hemoglobin level and BMI score of S-point group and Non S-point group.
| 12.69 (±1.99) | 13.16 (±2.37) | 0.266 | |
| 23.41 (±3.71) | 24.93 (±3.97) | 0.039 |
Hb, Hemoglobin; BMI, Body Mass Index.
Indicate statistically significant (p-value < 0.05).